公开(公告)号：EP1937312A2

公开(公告)日：2008-07-02

申请号：EP06802842.2

申请日：2006-08-29

申请人： Isis Pharmaceuticals, Inc. ,  Ercole Biotech, Inc.

发明人： BENNETT, C. Frank ,  DEAN, Nicholas, M. ,  KOLE, Ryszard ,  KOPCZYNSKI, Casey, C.

IPC分类号： A61K48/00

CPC分类号： C12N15/113 ,  C12N15/111 ,  C12N15/1135 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/346 ,  C12N2320/33 ,  C12N2310/3525 ,  C12N2310/3533 ,  C12N2310/3531

摘要： Disclosed herein are compounds, compositions and methods for modulating splicing of a selected target mRNA. Further provided are uses of the disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Methods of enhancing cellular uptake, modulating tissue distribution and enhancing pharmacological activity of RNase H-independent antisense oligonucleotides are also provided.

公开(公告)号：EP1937312B1

公开(公告)日：2016-06-29

申请号：EP06802842.2

申请日：2006-08-29

申请人： Ionis Pharmaceuticals, Inc. ,  Ercole Biotech, Inc.

发明人： BENNETT, C. Frank ,  DEAN, Nicholas, M. ,  KOLE, Ryszard ,  KOPCZYNSKI, Casey, C.

IPC分类号： C12N15/11 ,  C12N15/113

CPC分类号： C12N15/113 ,  C12N15/111 ,  C12N15/1135 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/346 ,  C12N2320/33 ,  C12N2310/3525 ,  C12N2310/3533 ,  C12N2310/3531

公开(公告)号：EP2331141A2

公开(公告)日：2011-06-15

申请号：EP09819622.3

申请日：2009-08-25

申请人： Excaliard Pharmaceuticals, Inc. ,  Isis Pharmaceuticals, Inc.

发明人： DEAN, Nicholas, M. ,  FOULKES, J. Gordon ,  O`DONNELL, Niall ,  BENNETT, C. Frank ,  FREIER, Susan M.

IPC分类号： A61K48/00

CPC分类号： C12N15/1136 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2320/30 ,  C12N2310/3521

摘要： This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.

公开(公告)号：EP0714449A1

公开(公告)日：1996-06-05

申请号：EP94923932.0

申请日：1994-07-08

申请人： ISIS PHARMACEUTICALS, INC.

发明人： BENNETT, C. Frank ,  BOGGS, Russell T. ,  DEAN, Nicholas M.

IPC分类号： C12N15 ,  A61K31 ,  A61K48 ,  A61P29 ,  A61P35 ,  A61P43 ,  C07H21 ,  C07K14 ,  C12N5 ,  C12N9 ,  C12Q1 ,  G01N33 ,  A61K38

CPC分类号： C12N15/1137 ,  A61K38/00 ,  A61K48/00 ,  C07H21/00 ,  C07K14/70564 ,  C12N9/12 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3521 ,  C12N2310/3527 ,  C12N2310/3533 ,  C12Q1/6876 ,  C12Q1/6883 ,  C12Q2600/158 ,  C12Y207/11013

摘要： Compositions and methods are provided for the treatment and diagnosis of diseases associated with protein kinase C. Oligonucleotides are provided which are specifically hybridizable with a PKC gene or mRNA. Oligonucleotides specifically hybridizable with a particular PKC isozyme, set of isozymes or mRNA transcript are provided. Methods of treating conditions amenable to therapeutic intervention by modulating protein kinase C expression with an oligonucleotide specifically hybridizable with a PKC gene or mRNA are disclosed. Compositions and methods are provided for the treatment, detection and diagnosis of diseases associated with protein kinase Calpha and specific transcripts thereof. New nucleic acid sequences are provided which encode 3' untranslated regions of human protein kinase Calpha. Polynucleotide probes for PKCalpha are also disclosed.

公开(公告)号：EP2906697A1

公开(公告)日：2015-08-19

申请号：EP13847099.2

申请日：2013-10-15

申请人： Isis Pharmaceuticals, Inc. ,  The Johns Hopkins University

发明人： BENNETT, C. Frank ,  FREIER, Susan M. ,  ROTHSTEIN, Jeffrey D. ,  DONNELLY, Christopher ,  SATTLER, Rita, G.

IPC分类号： C12N15/11 ,  C12N5/00 ,  C12N5/071 ,  C12Q1/68

CPC分类号： C12N15/113 ,  A61K31/7088 ,  C12N2310/11 ,  C12N2310/111 ,  C12N2310/113 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12N2310/3521

摘要： Disclosed herein are methods for monitoring expression of C9ORF72 mRNA and protein in an animal with C9ORF72 specific inhibitors. Such C9ORF72 specific inhibitors include antisense compounds.

公开(公告)号：EP2831232A1

公开(公告)日：2015-02-04

申请号：EP13770075.3

申请日：2013-03-14

申请人： Washington University ,  Isis Pharmaceuticals, Inc.

发明人： MILLER, Timothy M. ,  DEVOS, Sarah ,  BENNETT, C. Frank ,  RIGO, Frank

IPC分类号： C12N15/11 ,  C07H21/00

CPC分类号： C12N15/113 ,  C07H21/02 ,  C07H21/04 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525

摘要： Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.

摘要翻译： 本文公开了用Tau反义化合物降低动物中Tau mRNA和蛋白质表达的方法。 还公开了用Tau反义化合物调节动物中Tau mRNA的剪接的方法。 此类方法可用于治疗，预防或改善有需要的个体中的神经变性疾病。 可以通过施用Tau反义寡核苷酸治疗，预防和改善的神经变性疾病的实例包括阿尔茨海默氏病，额颞叶痴呆（FTD），FTDP-17，进行性核上性麻痹，慢性创伤性脑病，癫痫和Dravet综合征。

公开(公告)号：EP2331141B1

公开(公告)日：2016-01-06

申请号：EP09819622.3

申请日：2009-08-25

申请人： Excaliard Pharmaceuticals, Inc. ,  Isis Pharmaceuticals, Inc.

发明人： DEAN, Nicholas, M. ,  FOULKES, J. Gordon ,  O`DONNELL, Niall ,  BENNETT, C. Frank ,  FREIER, Susan M.

IPC分类号： C12N15/113 ,  A61K31/7088 ,  A61K48/00

CPC分类号： C12N15/1136 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2320/30 ,  C12N2310/3521

摘要： This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.

公开(公告)号：EP2906696A1

公开(公告)日：2015-08-19

申请号：EP13846313.8

申请日：2013-10-15

申请人： Isis Pharmaceuticals, Inc. ,  Ludwig Institute For Cancer Research Limited ,  The Regents of the University of California

发明人： RIGO, Frank ,  CLEVELAND, Don W. ,  LAGIER-TOURENNE, Clotilde ,  RAVITS, John M. ,  BENNETT, C. Frank ,  FREIER, SUSAN M. ,  BAUGHN, Michael W.

IPC分类号： C12N15/11 ,  A61K48/00

CPC分类号： C12N15/113 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/3181 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/321 ,  C12N2310/3525

摘要： Disclosed herein are methods for reducing expression of C90RF72 mRNA and protein in an animal with C90RF72 specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C90RF72 specific inhibitors include antisense compounds. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration C90RF72 specific inhibitors include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), corticalbasal degeneration syndrome (CBD), atypical Parkinsonian syndrome, and olivopontocerellar degeneration (OPCD).